Celldex Therapeutics, Inc. Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired
Celldex Therapeutics, Inc. (CLDX) reported Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired of $1.70 million for the 12-month period ending 2016-12-31, per its 10-Q filed 2020-11-05.
Discontinued › Notes › Goodwill and Other
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired · last filed 2020-11-05
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired 12 month |
|---|---|
| 2016-12-31 | $1.70M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |